Maraba virus as a potent oncolytic vaccine vector

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 420-429

  Pol, Jonathan G ^a   Zhang, Liang ^a   Bridle, Byram W ^a,b   Stephenson, Kyle B ^a,c   Rességuier, Julien ^a   Hanson, Stephen ^a   Chen, Lan ^a   Kazdhan, Natasha ^a   Bramson, Jonathan L ^a   Stojdl, David F ^d   Wan, Yonghong ^a   Lichty, Brian D ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS VECTOR; CANCER VACCINE; DOPACHROME ISOMERASE; ISOMERASE; ONCOLYTIC VIRUS;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER MODEL; CANCER REGRESSION; CELLULAR IMMUNITY; FEMALE; GENETIC ENGINEERING; IMMUNOMODULATION; MARABA VIRUS MG1; MELANOMA; MOUSE; NONHUMAN; RHABDOVIRUS; SURVIVAL RATE; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR XENOGRAFT; VIRUS ATTENUATION; VIRUS STRAIN; ANIMAL; CD8+ T LYMPHOCYTE; CYTOPATHOGENIC EFFECT; EXPERIMENTAL MELANOMA; GENE EXPRESSION; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; LUNG NEOPLASMS; MORTALITY; NEOPLASMS; PATHOLOGY; PROCEDURES; RHABDOVIRIDAE; SECONDARY; TREATMENT OUTCOME; VESICULOVIRUS; VIRAL TROPISM;

ANIMALIA; MURINAE; MUS; RHABDOVIRIDAE;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; IMMUNIZATION, SECONDARY; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; ONCOLYTIC VIRUSES; RHABDOVIRIDAE; TREATMENT OUTCOME; VESICULOVIRUS; VIRAL TROPISM;

EID: 84895909418     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.249     Document Type: Article

References (30)

1. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670.
2. Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
3. Karapanagiotou, EM, Roulstone, V, Twigger, K, Ball, M, Tanay, M, Nutting, C et al. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18: 2080-2089.
4. Harrington, KJ, Hingorani, M, Tanay, MA, Hickey, J, Bhide, SA, Clarke, PM et al. (2010). Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res 16: 4005-4015.
5. Miest, TS, Yaiw, KC, Frenzke, M, Lampe, J, Hudacek, AW, Springfeld, C et al. (2011). Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 19: 1813-1820.
6. White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920.
7. Law, M, Hollinshead, R and Smith, GL (2002). Antibody-sensitive and antibodyresistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibodyresistant spread. J Gen Virol 83(Pt 1): 209-222.
8. Chen, Y, Yu, DC, Charlton, D and Henderson, DR (2000). Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 11: 1553-1567.
9. Brun, J, McManus, D, Lefebvre, C, Hu, K, Falls, T, Atkins, H et al. (2010). Identification of genetically modified maraba virus as an oncolytic rhabdovirus. Mol Ther 18: 1440-1449.
10. Mahoney, DJ, Lefebvre, C, Allan, K, Brun, J, Sanaei, CA, Baird, S et al. (2011). Virustumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell 20: 443-456.
11. Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
12. Pol J, Rességuier J and Lichty B (2011). Oncolytic viruses: a step into cancer immunotherapy. Vir Adapt Treat 2012: 1-21.
13. Bridle, BW, Li, J, Jiang, S, Chang, R, Lichty, BD, Bramson, JL et al. (2010). Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol 184: 4269-4275.
14. Pulido, J, Kottke, T, Thompson, J, Galivo, F, Wongthida, P, Diaz, RM et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol 30: 337-343.
15. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
16. Bridle, BW, Boudreau, JE, Lichty, BD, Brunellière, J, Stephenson, K, Koshy, S et al. (2009). Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 17: 1814-1821.
17. Draper, SJ and Heeney, JL (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8: 62-73.
18. Aurisicchio, L, Mennuni, C, Giannetti, P, Calvaruso, F, Nuzzo, M, Cipriani, B et al. (2007). Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 120: 2290-2300.
19. Facciabene, A, Aurisicchio, L, Elia, L, Palombo, F, Mennuni, C, Ciliberto, G et al. (2006). DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther 17: 81-92.
20. Mennuni, C, Calvaruso, F, Facciabene, A, Aurisicchio, L, Storto, M, Scarselli, E et al. (2005). Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117: 444-455.
21. Breitbach, CJ, De Silva, NS, Falls, TJ, Aladl, U, Evgin, L, Paterson, J et al. (2011). Targeting tumor vasculature with an oncolytic virus. Mol Ther 19: 886-894.
22. Wang, LC, Lynn, RC, Cheng, G, Alexander, E, Kapoor, V, Moon, EK et al. (2012). Treating tumors with a vaccinia virus expressing IFNß illustrates the complex relationships between oncolytic ability and immunogenicity. Mol Ther 20: 736-748.
23. Endo, Y, Sakai, R, Ouchi, M, Onimatsu, H, Hioki, M, Kagawa, S et al. (2008). Virusmediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 27: 2375-2381.
24. Errington, F, Steele, L, Prestwich, R, Harrington, KJ, Pandha, HS, Vidal, L et al. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180: 6018-6026.
25. Benencia, F, Courrèges, MC, Fraser, NW and Coukos, G (2008). Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 7: 1194-1205.
26. Benencia, F, Courrèges, MC, Conejo-García, JR, Mohamed-Hadley, A, Zhang, L, Buckanovich, RJ et al. (2005). HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 12: 789-802.
27. Bridle, BW, Chen, L, Lemay, CG, Diallo, JS, Pol, J, Nguyen, A et al. (2013). HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 21: 887-894.
28. Lane, C, Leitch, J, Tan, X, Hadjati, J, Bramson, JL and Wan, Y (2004). Vaccinationinduced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 64: 1509-1514.
29. Ng, P, Beauchamp, C, Evelegh, C, Parks, R and Graham, FL (2001). Development of a FLP/frt system for generating helper-dependent adenoviral vectors. Mol Ther 3(5 Pt 1): 809-815.
30. Lawson, ND, Stillman, EA, Whitt, MA and Rose, JK (1995). Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92: 4477-4481.